Summary of Aimeike's Conference Call Company Overview - Aimeike is one of the largest publicly listed companies in the medical aesthetics industry in China, transitioning from a single product model to a platform-based company by acquiring the Korean company Region [4][5] Financial Performance - In the first half of 2025, Aimeike's net profit attributable to the parent company, excluding non-recurring items, was 722 million yuan, a year-on-year decline of 33.7% - The decline in net profit accelerated in Q2 2025, dropping to 320 million yuan, a decrease of 42.8% compared to the previous year, primarily due to a slowdown in market conditions and pressure on terminal demand [2][4] Market Competition - Core products such as the "Milky Angel" and "Happy" series are facing increasing competition, which is expected to impact overall performance [2][4] New Product Development - The new product "Zhen Ai Su Fei" has begun team recruitment and shipping, with expectations to reach about one-third of the sales volume of the medical aesthetics group's "Tong Yan" series [2][5] - Aimeike is hiring experienced professionals in high-end medical aesthetic injection products to accelerate the product launch cycle and improve market engagement [6] Sales Strategy - Aimeike employs a direct sales and distribution model, achieving the highest channel engagement rate in the Chinese medical aesthetics industry [3][8] - The company is implementing sales incentive mechanisms to boost team morale and performance, which is expected to solidify market position and facilitate rapid market entry for new products [3][8] Future Outlook - Investors should monitor the trend of stabilizing declines in old business lines, with expectations for improvement in Q4 2025 - The new product "Zhen Ai Su Fei" is projected to generate several hundred million yuan in revenue this year, with potential to reach higher levels in 2026 [7] - Future product launches, including botulinum toxin and fat reduction products, are anticipated to create synergistic effects with existing channels, enhancing profitability [7] Overall Investment Sentiment - The overall net profit expectation for Aimeike in 2025 is approximately 1.6 billion yuan, reflecting a relatively positive outlook despite current challenges [7]